A Randomized Phase III Study of Bendamustine Plus Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib Alone in Untreated Older Patients (greater than or equal to 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 15 Apr 2018
At a glance
- Drugs Bendamustine (Primary) ; Ibrutinib (Primary) ; Rituximab
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 10 Apr 2018 Planned primary completion date changed from 25 Mar 2018 to 16 May 2018.
- 10 Jun 2017 Biomarkers information updated
- 29 Dec 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.